Minnesota is currently home to 2074 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04671667
Recruiting
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as p... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
05/07/2025
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
NCT04585958
Recruiting
This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum resistant). Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of deoxyribonucleic acid (DNA) damage. Blocking this enzyme may help keep tumor cells from repa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
Register for Updates
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Fairview Ridges Hospital, Burnsville, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Fairview Health Services, Maplewood, Minnesota
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
Adrenoleukodystrophy National Registry Study
NCT03789721
Recruiting
The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.
Gender:
ALL
Ages:
All
Trial Updated:
05/07/2025
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: ALD (Adrenoleukodystrophy), Adrenoleukodystrophy, Cerebral Adrenoleukodystrophy
Register for Updates
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
Recruiting
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including affordability, time, and age, not all patients are able to be screened. Researchers are working on other options for early detection that are as accurate as colonoscopy. The purpose of this study if to determine if stool... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Colonic Neoplasms
Register for Updates
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
NCT06891222
Recruiting
The purpose of this study is to evaluate and compare the effectiveness of active screening for SHD in asymptomatic outpatients referred for an ECG, using a combination of AI-ECG and FOCUS. Invites will be sent and participants enrolled electronically.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cardiac Disease
Register for Updates
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910
Recruiting
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Minnesota Oncology Hematology, Maple Grove, Minnesota
Conditions: Limited Stage Small Cell Lung Cancer
Register for Updates
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Recruiting
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Advanced Breast Cancer
Register for Updates
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT06524882
Recruiting
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logM... Read More
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
05/06/2025
Locations: Zenith Vision Development Center, Duluth, Minnesota
Conditions: Amblyopia
Register for Updates
Bionic Pancreas in CFRD
NCT06449677
Recruiting
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to us... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
05/06/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cystic Fibrosis-related Diabetes
Register for Updates
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
NCT06333652
Recruiting
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/06/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Preeclampsia
Register for Updates